HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.

Takaaki ObaMayu OnoHisanori MatobaTakeshi UeharaYoshie HasegawaKen-Ichi Ito

Published in: Breast cancer research and treatment (2021)

HDAC6 inhibition enhances the anti-tumor effect of eribulin through the acetylation of α-tubulin. This combination therapy could represent a novel therapeutic strategy for TNBC.

Keyphrases

combination therapy
histone deacetylase
breast cancer cells
metastatic breast cancer
phase ii
clinical trial
randomized controlled trial
open label
study protocol